Clinical trial
Randomized, Double-Blind, Placebo-Controlled, Phase 3 Induction Study to Assess the Efficacy and Safety of 6µg Sargramostim (Leukine) Administered Subcutaneously Once Daily for 8 Weeks in Patients With Active Crohn's Disease
NCT00295165 is registered in ClinicalTrials.gov with Genzyme, a Sanofi Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized, Double-Blind, Placebo-Controlled, Phase 3 Induction Study to Assess the Efficacy and Safety of 6µg Sargramostim (Leukine) Administered Subcutaneously Once Daily for 8 Weeks in Patients With Active Crohn's Disease
- Lead sponsor
- Genzyme, a Sanofi Company
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- January 31, 2006
- Completion date
- October 31, 2006
- Enrollment
- 33 (actual)
- Sites
- 111
Conditions
As the registry lists them; a condition with its own page is linked.